Estrogens in vascular biology and disease:: where do we stand today?

被引：59
|
作者：
Arnal, Jean-Francois
Scarabin, Pierre-Yves
Tremollieres, Florence
Laurell, Henrik
Gourdy, Pierre
机构：
[1] CHU Toulouse Rangueil, Dept Vasc Biol & Atherothrombosis, INSERM, U858,12MR, F-31432 Toulouse 4, France
[2] Hop Paul Brousse, Cardiovasc Epidemiol Team, Villejuif, France
来源：
CURRENT OPINION IN LIPIDOLOGY | 2007年 / 18卷 / 05期
关键词：
atheroma; atherosclerosis; cardiovascular risk; oestrogens; thrombosis;
D O I：
10.1097/MOL.0b013e3282ef3bca
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
A better understanding of the balance between the deleterious and beneficial effects of estrogens is required and should help to improve hormonal therapy safety and to optimize the prevention of cardiovascular disease after menopause.
引用
收藏
页码：554 / 560
页数：7
相关论文
共 50 条
  • [41] Non-steroidal anti-inflammatory drugs and atherothrombotic risk in older patients: where do we stand?
    Mangoni, Arduino A.
    Reid, David M.
    Knights, Kathleen M.
    AGE AND AGEING, 2010, 39 (05) : 530 - 533
  • [42] Therapeutic Strategies and Chemoprevention of Atherosclerosis: What Do We Know and Where Do We Go?
    Aprotosoaie, Ana Clara
    Costache, Alexandru-Dan
    Costache, Irina-Iuliana
    PHARMACEUTICS, 2022, 14 (04)
  • [43] Cardiac biomarker testing in the clinical laboratory: Where do we stand? General overview of the methodology with special emphasis on natriuretic peptides
    Clerico, Aldo
    Passino, Claudio
    Franzini, Maria
    Emdin, Michele
    CLINICA CHIMICA ACTA, 2015, 443 : 17 - 24
  • [44] Vitamin E: Where Are We Now in Vascular Diseases?
    Garg, Anahita
    Lee, Jetty Chung-Yung
    LIFE-BASEL, 2022, 12 (02):
  • [45] The mechanisms of Chr.9p21.3 risk locus in coronary artery disease: where are we today?
    Ruotsalainen, Anna-Kaisa
    Kettunen, Sanna
    Suoranta, Tuisku
    Kaikkonen, Minna U.
    Yla-Herttuala, Seppo
    Aherrahrou, Redouane
    AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2025, 328 (02): : H196 - H208
  • [46] The behavioural epidemiology of sedentary behaviour in inflammatory arthritis: where are we, and where do we need to go?
    Fenton, Sally A. M.
    O'Brien, Ciara M.
    Kitas, George D.
    Duda, Joan L.
    van Zanten, Jet J. C. S. Veldhuijzen
    Metsios, George S.
    RHEUMATOLOGY ADVANCES IN PRACTICE, 2022, 7 (01)
  • [47] Vascular Disease in the Metabolic Syndrome: Do We Need to Target the Microcirculation to Treat Large Vessel Disease?
    Krentz, Andrew J.
    Clough, Geraldine
    Byrne, Christopher D.
    JOURNAL OF VASCULAR RESEARCH, 2009, 46 (06) : 515 - 526
  • [48] Inflammatory Diseases and Vitamin E-What Do We Know and Where Do We Go?
    Wallert, Maria
    Boermel, Lisa
    Lorkowski, Stefan
    MOLECULAR NUTRITION & FOOD RESEARCH, 2021, 65 (01)
  • [49] Apolipoproteins in vascular biology and atherosclerotic disease
    Mehta, Anurag
    Shapiro, Michael D.
    NATURE REVIEWS CARDIOLOGY, 2022, 19 (03) : 168 - 179
  • [50] An Evolving Understanding of the Basis and Management of Vascular Complications of COVID-19: Where Do We Go From Here?
    Szekely, Yishay
    Gilead, Rami
    Rea, Ana Beatriz B. A. C.
    Lawler, Patrick R.
    CANADIAN JOURNAL OF CARDIOLOGY, 2023, 39 (06) : 865 - 874
12345